GeneFerm Biotechnology Co., Ltd. (1796.TWO)
Taipei Exchange · TWD · Healthcare · Drug Manufacturers - Specialty & Generic
NT$27.80 (-0.18%) as of
Key statistics
- Market cap
- 1.15B
- P/E (TTM)
- 66.19
- EPS (TTM)
- 0.42
- Dividend yield
- 2.51%
- 52-week range
- 27.10 – 52.50
- Beta
- 0.08
- Revenue (TTM)
- 664.93M
- Profit margin
- 2.57%
- Volume
- 24.00k
About GeneFerm Biotechnology Co., Ltd.
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company provides microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reishi mycelia, phellinus linteus mycelia powder, armillaria mellea mycelia powder, beta-glucan powder, and fruits and vegetables fermented enzyme, as well as probiotics and peptide ingredients. It also provides private label supplements; and microbial fermentation toll manufacturing services. The company was founded in 1999 and is headquartered in Tainan City, Taiwan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Tainan City, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.